Official action initiation report by USFDA on Puducherry plant (~7% of the total revenue of SS) was an unexpected event. The management is optimistic of transfer of production to other locations (5 of 6 products). US business grew by 31%QoQ driven by healthy performance in the base portfolio with no major price erosions and strong filing momentum (~21). Australian business saw a flat growth rate with a total of 18 new releases in FY19 while they received shareholders approval to exit Arrow investments which is expected to pay ~Rs1500cr upfront once effected....